Comparison of Nerve-sparing Techniques in Radical Prostatectomy for Oncological Outcome and Functional Recovery.

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Jul 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at different techniques used during surgery for prostate cancer to see how they affect both cancer outcomes and recovery afterwards. Specifically, the study will compare three approaches: one that spares nerves on one side, one that spares nerves on both sides, and one that does not spare nerves. The goal is to find out which method might offer the best results for patients.

To be eligible for this trial, men aged between 18 and 80 who have been diagnosed with localized prostate cancer that hasn't spread beyond the prostate are being considered. Participants should also be in good health and able to undergo robot-assisted surgery. If you join this trial, you can expect to receive the surgery and be monitored closely for your recovery and any impacts on your cancer. It’s important to know that this study is not yet recruiting participants, so it will be a little while before anyone can take part.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Men aged ≥18 years and ≤80 years;
• • Histologically proven prostate adenocarcinoma with clinical stage \< T3(no capsule break)
• • Clinically localized prostate cancer in very low, low, or intermediate risk groups according to National Comprehensive Cancer Network(NCCN) guidelines (2019 v4) ;
• • Eastern Cooperative Oncology Group(ECOG) score of 0 or 1;
• • Life expectancy greater than 10 years;
• • Patients who are willing to accept robot-assisted radical prostatectomy after informed existing treatment plan, must sign the informed consent form.
• Exclusion Criteria:
• • Surgeon thinks that the patient has an unresectable disease;
• • patients who have already applied androgen deprivation therapy(ADT);
• • Preoperative images suggest that the local lymph nodes were larger than 2 cm or suggest bone or distant metastasis;
• • Any contraindication;
• • Previous treatment of prostate cancer, including but not limited to surgery, hormone therapy, chemotherapy, radiotherapy, targeted therapy and immunotherapy;
• • Patients with a history of transurethral resection or enucleation of the prostate;
• • Severe systemic disease that may interfere with the data, assessment, or compliance;
• • Patients who are participating in other clinical trials;
• • Refusing to sign the informed consent
• • Patients that are considered to be not suitable to be included by the researchers.